ginsenoside rh2 has been researched along with Alzheimer Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Feng, SH; He, ZY; Li, W; Qiu, J; Wang, M | 1 |
| Cheng, JT; Kou, DH; Li, JS; Shieh, PC; Tsao, CW; Wen, YJ; Wu, HT | 1 |
2 other study(ies) available for ginsenoside rh2 and Alzheimer Disease
| Article | Year |
|---|---|
Ginsenoside Rh2 promotes nonamyloidgenic cleavage of amyloid precursor protein via a cholesterol-dependent pathway.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Animals; Cholesterol; Disease Models, Animal; Ginsenosides; Hippocampus; Metabolic Networks and Pathways; Mice; Neurons; Peptide Fragments | 2014 |
Role of pituitary adenylate cyclase-activating polypeptide (PACAP) in the action of ginsenoside Rh2 against beta-amyloid-induced inhibition of rat brain astrocytes.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Animals, Newborn; Astrocytes; Brain; Cell Line; Cell Proliferation; Estrogen Antagonists; Ginsenosides; Neuroprotective Agents; Pituitary Adenylate Cyclase-Activating Polypeptide; Plaque, Amyloid; Rats; Rats, Wistar; Receptors, Estrogen; Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide, Type I; Up-Regulation | 2008 |